Background: The treatment of atrial fibrillation (AF) includes anticoagulation (AC) therapy to prevent systemic emboli. Until recently, warfarin was the main AC agent, while in recent years, the new oral anticoagulants (NOACs) are increasingly being used. Aim: The aim of our study was to characterize the AC treatment policy of AF patients at the department of medicine in the NOACs era. Methods and Design: An observational study of consecutive hospitalized patients with non-valvular AF for a period of 3 months in Beilinson hospital (January to March 2017). Demographic characteristics, clinical data and AC therapeutic approach were compared to those from the pre-NOACs era, based on a previous study. Results: A total of 335 patients were hospitalized with either new (21%) or prior (79%) non-valvular AF. An increase in AC therapy among patients with prior and new AF was observed compared to the pre-NOACs era (76% vs. 59%; P < 0.001 and 68% vs. 49%; P < 0.001, respectively). Totally, 76% of all patients were discharged with AC therapy compared to 55% in the pre-NOACs era. As in the pre-NOACs era, prior AC therapy was the main predictor for the prescription of AC therapy during hospitalization and discharge (OR ¼ 13, 95% CI; 7-25, P ¼ 0.0001). Conclusion: There is a significant increase in the AC therapy prescription, mainly NOACs, in hospitalized non-valvular AF patients. This increase could be explained by the difficulties in warfarin treatment and the benefits of NOACs. Nevertheless, a large observational study is required to prove these findings.
Introduction
The therapeutic approaches to atrial fibrillation (AF) include rhythm or rate control, in which the goal is to restore and maintain sinus rhythm or slowing the heart rate. Regardless of the approach, each patient should be treated by anticoagulation (AC) agents to prevent systemic emboli, mainly stroke. 1 Until recently, the oral vitamin K antagonist, warfarin, was the main agent, whereas nowadays the new oral anticoagulants (NOACs) have become available and increasingly used. These agents have been found to be more effective and mainly safer to use than warfarin and are recommended by all guidelines for the treatment of non-valvular AF. [2] [3] [4] [5] Since 2015 the Israeli basic health program approved NOACs for the treatment of nonvalvular AF in patients with CHADS 2 score 2. Our previous study, prior to the introduction of the NOACs, revealed that 45% of the hospitalized patients with non-valvular AF were not treated by anticoagulants, the rate of AC treatment did not significantly differ between the CHA 2 DS 2 _Vasc2 score levels and that hospitalization did not affect the approach to AC therapy with the main predictor of AC therapy was its use prior to hospitalization. 6 We estimate that in the NOACs era, the data regarding the rate of AC therapy and its use during hospitalization have been significantly increased.
The aim of our study was to re-characterize the patients with non-valvular AF hospitalized at the department of medicine and their AC treatment policy in the NOACs era.
Materials and methods

Study design and population
The study design was identical to our previous one. 6 A retrospective study based on the medical records of patients with non-valvular AF who were hospitalized in departments of medicine at a tertiary hospital during a period of three consecutive months (January to March 2017). Non-valvular AF patient was defined as AF patient without rheumatic valvular disease predominantly mitral stenosis or mechanical heart valves. 7 Data regarding patients' demographics (age and gender); comorbidities (ischemic heart disease, congestive heart disease, peripheral vascular disease, diabetes mellitus, hypertension, hyperthyroidism, chronic lung disease, chronic kidney disease, past or active malignancies); diagnosis of AF (new or preexisting); laboratory results at admission (hemoglobin, platelets count and creatinine level); the mean of INR levels during 3 months prior to admission in patients on warfarin, rhythm or rate control policy; and AC therapy at both admission and discharge (including warfarin, NOACs and enoxaparin). CHA 2 DS 2 _Vasc2 and HASBLED scores were also calculated for each patient.
All demographic and clinical data were compared to the ones from the pre-NOACs era, based on our previous study. 6 
Statistical analysis
Continuous variables were expressed as mean, while categorical data were summarized as frequencies and percentages of patients. The predictors for prescribing NOACs during hospitalization were developed by univariate analysis. All P-values were two-sided, a P values <0.05 were considered significant. Analyses were conducted with SPSS software, version 24.
Results
During the study period, 335 patients were hospitalized in 6 internal medicine wards with either diagnosis of new or prior nonvalvular AF. Table 1 provides the baseline characteristics of the study group. The mean age was 79 6 11 years, half males. The most common co-morbidities were hypertension (76%), diabetes mellitus (42%) and ischemic heart disease (41%). The main admission causes were cardiac (35%) followed by infectious diseases (21%). Half of the patients had more than three co-morbidities. All baseline characteristics did not differ significantly from the ones, reported in the previous study (Supplementary Table S1 ). Table 2 shows the AF characteristics. Totally, 79% of the patients had a prior diagnosis of AF while 21% had a new diagnosis at admission or during hospitalization. About 87% were at high risk for stroke (CHA 2 DS 2 _Vasc2 score 3) while 53% were at increased risk for bleeding (HASBLED score 3). All these characteristics were similar to the ones reported in the previous study (Supplementary Table S2 ).
AF characteristics
Patients with prior AF (n 5 263)
The characteristics of the 263 patients with prior AF are provided in Table 2 . About 62% of them were treated by rate control compared to 73% in the previous study. 6 Three-quarters (76%) were treated with AC therapy prior to hospitalization, compared with only 59% in the pre-NOACs era. 6 A total of 56% were treated by NOACs, 17% by warfarin, while in 47% of them the INR levels were in therapeutic range (2-3.4). In the pre-NOACs era, the picture was completely different. About 46% of patients were treated with warfarin, while 39% had INR levels within the therapeutic range (Supplementary Table S2 ). The number of patients treated by AC therapy remained almost unchanged during hospitalization (24%-22%); however a slight increase (5%) was recorded in the NOACs registry during hospitalization. Most patients on warfarin remained on it during hospitalization (16%) ( Figure 1A ).
Patients with new AF (n 5 72)
The characteristics of the 72 patients with a new diagnosis of AF, at admission or during hospitalization, are shown in Table 2 . About 63% of them were treated by rate control. AC therapy was started in 67% of them, compared with only 49% in the pre-NOACs era. 6 The most common anticoagulants were NOACs (50%) ( Figure 1B) . Figure 2 provides the percentages of AC and anti-platelets therapy according the CHA 2 DS 2 _Vasc2 score levels, with no significant correlation between AC therapy rates and the increased risk score. These findings did not differ significantly from those in the pre-NOACs era (Supplementary Figure S2) .
Overall, 76% (254/335) of patients with new or previous diagnosis of AF were discharged with AC therapy (58% NOACs, 14% warfarin, and 4% in enoxaparin) in comparison with the preNOACs era, in which only 55% were treated with AC therapy (6% NOACs, 46% warfarin and 3% enoxaparin). 6 
Predictors for AC therapy prescription
The predictors for AC therapy prescription during hospitalization are presented in Table 3 .
Prior AC therapy was the only significant predictor for the prescription of AC therapy during hospitalization and discharge (OR ¼ 13, 95% CI; 7-25, P ¼ 0.0001). Age 75 years, co-morbidities such as congestive heart failure or prior stroke, increased serum creatinine level were not significant predictors. Predictors of not prescribing AC therapy were anemia, active malignancy and prior anti platelets treatment. These findings did not differ from the ones at the previous study (Supplementary Table S3) .
Discussion
In the current study, we compared the AC therapeutic approach in non-valvular AF patients in the NOACs era with our previous study results at the time prior to the NOACs introduction. 6 The results showed a clear increase in the percentage of patients who were discharged on AC therapy (76% vs. 59%, P < 0.001), most of them were treated with NOACs. There was a significant increase in AC treatment among patients with new AF (68% vs. 49%, P < 0.001), half of them receiving NOACs. The rate of AC therapy was not in any correlation with the CHA 2 DS 2 _Vasc2 score levels. The main predictor of AC therapy was its use prior to the admission, similar to our findings in the previous study. 6 There are several explanations for this change in AC therapeutic approach, including: the difficulties in the use of warfarin due to its narrow therapeutic index, which require frequent dose adjustment and monitoring compared to the NOACs; the fact that some NOACs are more effective and mainly safer than warfarin; fewer interactions of the NOACs with food and drugs, On the other hand, despite the explicit guidelines recommendation there was no significant shift from warfarin to NOACs in patients with AF prior to hospitalization. 7 We believe that this is due to a careful medical decision that was made before hospitalization and which could not be changed. Another possible reason is that most patients on warfarin had INR levels within the therapeutic range. Nevertheless, this explanation is also in contrary to the guidelines recommendation to prefer NOACs on warfarin. 7 As was found in the current study, our previous one as well as in the GARFEILD study, about one-third of patients with low risk of stroke (CHA 2 DS 2 _Vasc2 ¼ 0) were treated with anticoagulants. 6, 8 Similar to the findings prior to the NOACs era, there was no direct correlation between the increased risk for thromboembolic events and the rate of AC treatment. The ORBIT AF investigators noted that the risk gap was unique for hospitalized patients, whereas in outpatients there was a positive correlation between AC therapy and stroke risk. The negative correlation was particularly evident in patients with acute diseases, as the subjects in our studies, mainly because of the fear from bleeding. 6, [9] [10] [11] [12] [13] [14] [15] In the NOACs era, the predictor of AC therapy for AF patients was their previous use prior to the admission, while anti platelet treatment was a major cause for not prescribing them. Age, gender and co-morbidities including heart failure, stroke and renal failure were not significant predictors. Since in most cases the AF was pre-existing, these findings indicate that the main decision on the AC therapy was made prior to hospitalization, and since the clinical data did not change, there was no ground to change it.
The comparison between the two periods was highly reliable because they were performed at the same time in the same medical institution, and the characteristics of the patients were demographically and clinically almost identical.
The study has several limitations; first, being a retrospective one makes it vulnerable to collection bias and potential inaccuracies in data collection. Second, it is a single center study that limits its generalizability.
In conclusion, a larger observational study is needed to clarify our findings. 
